Affiliation:
1. Pharmaceutical College Tianjin Medical University Tianjin China
2. School of Statistics and Data Science Nankai University Tianjin China
3. Department of Pharmacy Tianjin First Central Hospital Tianjin China
Abstract
AbstractBackground and AimThe association between proton‐pump inhibitors (PPIs) and rhabdomyolysis were unclear. The aim of this study was to explore and systematically analyze the potential link between five PPIs and the rhabdomyolysis events using the FDA Adverse Event Reporting System (FAERS) database.MethodsSuspected rhabdomyolysis events associated with PPIs were identified by data mining with the reporting odds ratio (ROR), proportional reporting ratio (PRR), the information component (IC), and Empirical Bayes Geometric Mean (EBGM). Demographic information, drug administration, and outcomes of PPI‐induced rhabdomyolysis events were also analyzed.ResultsThere were 3311 reports associated with PPI‐induced rhabdomyolysis that were identified. After removing duplicates, 1899 cases were determined to contain complete patient demographic data. The average age was 65 ± 18 year and 57% were male. Omeprazole and pantoprazole had the same largest percentage of reports. Lansoprazole had the highest ROR index of 12.67, followed by esomeprazole (11.18), omeprazole (10.27), rabeprazole (10.06), and pantoprazole (9.24). PRR, IC, and EBGM showed similar patterns. This suggested that lansoprazole exhibited the strongest correlation with rhabdomyolysis. In rhabdomyolysis events, PPIs were mainly “concomitant” (>60%), and only a few cases were “primary suspects” (<15%). Rabeprazole showed the lowest death rate while lansoprazole showed the highest.ConclusionsThe study suggested that significant rhabdomyolysis signals were associated with PPIs. Further research should be performed in drug safety evaluation for a more comprehensive association.
Subject
Gastroenterology,Hepatology
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献